Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 3790.58% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 140.31% YoY), and the FY2025 full-year result was $3.7 billion, up 65.19% from the prior year.
• Revenue for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
• Across five years, Revenue topped out at $1.2 billion in Q3 2025 and bottomed at $30.0 million in Q1 2025.
• The 5-year median for Revenue is $494.3 million (2024), against an average of $554.8 million.
• The widest annual swing landed in 2025, when Revenue slumped 93.93%; it then surged 3790.58% in 2026.
• A 5-year view of Revenue shows it stood at $335.0 million in 2022, then jumped by 31.25% to $439.7 million in 2023, then surged by 34.9% to $593.2 million in 2024, then soared by 84.95% to $1.1 billion in 2025, then gained by 6.39% to $1.2 billion in 2026.
• The last three Revenue figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison